Workflow for the Implementation of Precision Genomics in Healthcare

To enable the implementation of precise genomics in a local healthcare system, we devised a pipeline for filtering and reporting of relevant genetic information to healthy individuals based on exome or genome data. In our analytical pipeline, the first tier of filtering is variant-centric, and it is based on the selection of annotated pathogenic, protective, risk factor, and drug response variants, and their one-by-one detailed evaluation. This is followed by a second-tier gene-centric deconstruction and filtering of virtual gene lists associated with diseases, and VUS-centric filtering according to ACMG pathogenicity criteria and pre-defined deleteriousness criteria. By applying this filtering protocol, we were able to provide valuable insights regarding the carrier status, pharmacogenetic profile, actionable cardiovascular and cancer predispositions, and potentially pathogenic variants of unknown significance to our patients. Our experience demonstrates that genomic profiling can be implemented into routine healthcare and provide information of medical significance.

[1]  E. Topol,et al.  The personal and clinical utility of polygenic risk scores , 2018, Nature Reviews Genetics.

[2]  Francisco M. De La Vega,et al.  Polygenic risk scores: a biased prediction? , 2018, Genome Medicine.

[3]  Matthew S. Lebo,et al.  The Impact of Whole-Genome Sequencing on the Primary Care and Outcomes of Healthy Adult Patients: A Pilot Randomized Trial. , 2017, Annals of internal medicine.

[4]  Man Li,et al.  Functional variants in NBS1 and cancer risk: evidence from a meta-analysis of 60 publications with 111 individual studies. , 2013, Mutagenesis.

[5]  R. Gibbs,et al.  Postmortem genetic screening for the identification, verification, and reporting of genetic variants contributing to the sudden death of the young , 2016, Genome research.

[6]  Alexander A. Morgan,et al.  Clinical assessment incorporating a personal genome , 2010, The Lancet.

[7]  T. Dörner,et al.  Marburg I polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism. , 2005, Blood.

[8]  W. Chung,et al.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.

[9]  J. McPherson,et al.  Coming of age: ten years of next-generation sequencing technologies , 2016, Nature Reviews Genetics.

[10]  Madeleine P. Ball,et al.  Predispositional genome sequencing in healthy adults: design, participant characteristics, and early outcomes of the PeopleSeq Consortium , 2019, Genome Medicine.

[11]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[12]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[13]  Helen E. Parkinson,et al.  The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog) , 2016, Nucleic Acids Res..

[14]  J. Mattick,et al.  Prioritising the application of genomic medicine , 2017, npj Genomic Medicine.

[15]  Max M. He,et al.  Challenges of Identifying Clinically Actionable Genetic Variants for Precision Medicine , 2016, Journal of healthcare engineering.

[16]  P. Gonzalez-Alegre,et al.  Towards precision medicine , 2017 .

[17]  F. Collins,et al.  Potential etiologic and functional implications of genome-wide association loci for human diseases and traits , 2009, Proceedings of the National Academy of Sciences.

[18]  W. Allan,et al.  Long QT Syndrome , 1998, Pediatrics.

[19]  P. Reitsma,et al.  A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. , 1996, Blood.

[20]  D. Milewicz,et al.  Heritable Thoracic Aortic Disease Overview , 2016 .

[21]  J. Sampson,et al.  MUTYH-associated polyposis. , 2009, Best practice & research. Clinical gastroenterology.

[22]  Dan M. Roden,et al.  Implementing genomic medicine in the clinic: the future is here , 2013, Genetics in Medicine.

[23]  J. Voorberg,et al.  Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V , 1994, The Lancet.

[24]  G. Breithardt,et al.  Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients , 2004, Journal of Molecular Medicine.

[25]  N. Arber,et al.  The APC I1307K allele conveys a significant increased risk for cancer , 2016, International journal of cancer.

[26]  B. Teh,et al.  Implementation of genomics in medical practice to deliver precision medicine for an Asian population , 2019, npj Genomic Medicine.

[27]  Matthew S. Lebo,et al.  A systematic approach to the reporting of medically relevant findings from whole genome sequencing , 2014, BMC Medical Genetics.

[28]  Lihong Liu,et al.  The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis. , 2013, DNA and cell biology.

[29]  Hui Yang,et al.  Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR , 2015, Nature Protocols.

[30]  P. C. Viswanathan,et al.  A sodium channel pore mutation causing Brugada syndrome. , 2007, Heart rhythm.

[31]  P. Peltomäki.  Role of DNA mismatch repair defects in the pathogenesis of human cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  D. Trujillano,et al.  A comprehensive global genotype–phenotype database for rare diseases , 2016, Molecular genetics & genomic medicine.